Moderna Vaccine: Europe Access Before US? | Medscape

The race to protect populations against both influenza and COVID-19 with a single vaccine is gaining momentum, but with a notable divergence between European and U.S. Regulatory pathways. The European Medicines Agency (EMA) has backed Moderna’s combined mRNA vaccine, potentially making it the first of its kind available in Europe, while the U.S. Food and Drug Administration (FDA) has, for now, declined to review the shot. This difference in approach raises questions about the speed of innovation and the factors influencing vaccine approval on either side of the Atlantic.

A Combined Approach to Respiratory Protection

Moderna’s mCombriax vaccine aims to simplify vaccination schedules and potentially increase uptake by offering protection against both seasonal influenza and COVID-19 with a single injection. The EMA’s recommendation, announced in late February 2026, covers individuals aged 50 and older. Reuters reports that this marks a significant step toward a more streamlined approach to respiratory virus prevention. The vaccine leverages messenger RNA (mRNA) technology – the same platform used in some of the most effective COVID-19 vaccines – to target both viruses simultaneously. MRNA vaccines work by delivering genetic instructions to cells, prompting them to produce proteins that trigger an immune response without introducing the virus itself.

Why the Disparity with the FDA?

The FDA’s decision not to review Moderna’s application at this time has sparked debate. Prompt Company highlights the contrast, questioning why Europe is moving forward while the U.S. Lags. Vinay Prasad, in an opinion piece for the Wall Street Journal, frames the situation as Europe “beating” the FDA, suggesting a difference in regulatory agility. The reasons for the FDA’s stance are complex and not fully public, but likely involve a more cautious approach to evaluating novel vaccine combinations and a desire for more comprehensive data. It’s important to note that the FDA’s decision isn’t necessarily a rejection of the vaccine’s potential, but rather a decision to postpone review pending further information or a more favorable risk-benefit profile.

Understanding the Evidence: Trial Data and Limitations

While detailed trial data is still emerging, Moderna has presented promising preliminary results for mCombriax. The vaccine’s efficacy against both influenza and COVID-19 has been evaluated in clinical trials, but the specific figures and the nuances of those results require careful scrutiny. It’s crucial to understand that vaccine efficacy rates are often presented as relative risk reductions, which can be misleading if not contextualized with baseline infection rates. For example, a 60% reduction in risk sounds substantial, but if the baseline risk of infection is low, the absolute risk reduction may be smaller. The trials’ design, the populations studied, and the circulating strains of influenza and COVID-19 all influence the results. Any reported efficacy is specific to the conditions under which the trial was conducted and may not perfectly translate to real-world scenarios.

What Does This Mean for Individuals?

For individuals in Europe, the EMA’s backing of mCombriax offers a potential convenience and simplification of their annual vaccination schedule. Instead of receiving separate flu and COVID-19 shots, they may soon be able to get both with a single dose. While, it’s important to remember that even with vaccination, breakthrough infections can still occur, and individuals should continue to practice other preventive measures, such as hand hygiene and staying home when sick. In the U.S., the current recommendation remains to receive separate, updated vaccines for both influenza and COVID-19, as advised by the Centers for Disease Control and Prevention (CDC). Individuals should consult with their healthcare providers to determine the best vaccination strategy for their individual circumstances.

The Public Health Process: Surveillance and Guidance Updates

Vaccine recommendations are not static; they evolve as latest data emerge and as the virus landscape changes. Public health agencies like the CDC and the ECDC (European Centre for Disease Prevention and Control) continuously monitor disease trends, vaccine effectiveness, and safety data. This surveillance informs updates to vaccination guidance. The process involves reviewing data from multiple sources, including clinical trials, real-world effectiveness studies, and adverse event reporting systems. These agencies also consider factors such as the severity of illness, the risk of complications, and the potential impact on healthcare systems. The FDA’s review process is similarly rigorous, involving multiple stages of evaluation and expert consultation.

Looking Ahead: What Comes Next for the Combined Vaccine?

The FDA’s decision is not necessarily final. Moderna could resubmit its application with additional data or address any concerns raised by the agency. The FDA may also request further information from Moderna before initiating a formal review. In Europe, the EMA’s recommendation is a crucial step, but final approval rests with the European Commission. If approved, the vaccine will then be rolled out across member states, with prioritization strategies varying by country. Ongoing surveillance will be essential to monitor the vaccine’s effectiveness and safety in real-world settings. Research will continue to explore the potential for even more advanced combination vaccines that could protect against a wider range of respiratory viruses. The development of mCombriax represents a significant advancement in vaccine technology, but it’s just one piece of the puzzle in the ongoing effort to combat infectious diseases.